Harbour Biomed Therapeutics Ltd., of Shanghai, appointed Xiaoxiang Chen executive vice president, head of clinical development and regulatory science. Read More
Opthea Ltd., of Melbourne, Australia, said it started a phase Ib/IIa trial testing OPT-302 in patients with center-involved diabetic macular edema (DME). The two-part design consists of a dose-escalation portion testing OPT-302 (0.3 mg, 1 mg and 2 mg) in combination with VEGF-A inhibitor Eylea (aflibercept, Regeneron Pharmaceuticals Inc.), followed by a phase IIa randomized, controlled dose expansion with treatment allocated in a 2-to-1 ratio to either OPT-302 with Eylea, or Eylea monotherapy. Read More
HONG KONG – Chinese biotech Zensun (Shanghai) Sci & Tech Co. Ltd., which focuses on innovative therapeutics for cardiovascular and energy metabolic diseases, has plans to raise about ¥500 million (US$76 million) from a consortium of investors, including a state-owned fund. Read More
NEW DELHI – The World Health Organization (WHO) has pre-qualified Indian company Bharat Biotech International Ltd.'s Typbar TCV, its conjugate vaccine against typhoid fever. The pre-qualification paves the way for possible use in childhood immunization programs against typhoid in high-risk, endemic countries. Read More
SHANGHAI – Xinogen (Hong Kong) Pharma Co. Ltd., a subsidiary of Beijing Shenogen Pharmaceuticals Group, has negotiated a deal with Angiochem Inc., of Montreal, to develop and sell ANG-1005, a paclitaxel-peptide drug conjugate for the treatment of leptomeningeal carcinomatosis from breast cancer. The deal gives Xinogen rights for greater China. Read More
HONG KONG – A consortium of Chinese investors will acquire a 90 percent stake in innovative oncology treatment developer Group NMS Co. Ltd., of Milan, Italy. The total value of the deal, including equity injection and debt restructuring, is around €300 million (US$361.25 million). Read More
HONG KONG – As one of the traditional pharmaceutical companies looking at innovative technologies to fuel its business in a country considering price caps for drugs, Japan's Sumitomo Dainippon Pharma Co. Ltd. has established a new laboratory to further expand efforts in the biopharmaceutical and genomics field. Read More
